Clinical trial
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization…
NCT00050817 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00050817 |
|---|---|
| Title | Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) |
| Official title | A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-dose ASA. |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arteriosclerosis |
| Intervention type | Drug |
| Interventions | clopidogrel (SR25990) |
| Enrollment | 15,603 |
| Start date | Oct 1, 2002 |
| Completion | Aug 1, 2005 |
| First posted | Dec 23, 2002 |
| Last update posted | Apr 23, 2012 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, Finland, France, Germany and 20 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: